$1.09
0.065.83%
Last update: Nov 10, 8:28 AM
Gain Therapeutics Inc (GANX) Stock Price, Quote, News & History
GANXNASDAQ
Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The company plans a Parkinson's disease...
You can purchase shares of Gain Therapeutics (NASDAQ:GANX) through any online brokerage.
Other companies in Gain Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Gain Therapeutics has a consensus price target of $7.56.
The stock price for Gain Therapeutics (NASDAQ: GANX) is $1.1 last updated November 10, 2026 at 8:28 AM EST.
There are no upcoming dividends for Gain Therapeutics.
Gain Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Gain Therapeutics.
Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs),...
